Stereotactic radiosurgery (SRS) is an evolving therapeutic modality for well demarcated intracranial lesions. Since the inception of stereotactic radiosurgery the types of parenchymal eNS lesions addressed by this mode of treatment has increased. All modern stereotactic radiosurgical procedures employ several common features. Patients are fitted with a stereotactic head frame or fiducial markers followed by radiographic imaging which allows for external reference points and three-dimensional mapping of the intracranial lesion.
Introduction
Stereotactic radiosurgery refers to a precise means specifically designed to deliver a highly conformal single fraction of radiation to a three-dimensionally defined target volume. Several forms of stereotactic radiosurgery are routinely used for the treatment of intracranial lesions including Gamma Knife (1), Linear accelerator based platforms (2) , and proton beams (3) . Currently SRS is employed for the treatment of benign and malignant intracranial lesions as well as some superiorly located head and neck malignancies. Examples of tumors treated by SRS include acoustic neuromas, arteriovenous malformations, gliomas, hemangioblastomas, intracranial metastasis, meningiomas and pituitary tumors. SRS is most frequently employed to treat discrete lesions less than 4 em in greatest dimension, often located deep in the brain parenchyma or near an eloquent region of the brain. Since its inception SRS has become an important and well-accepted alternative to conventional surgery and fractionated radiation therapy. With continued evolution of radiosurgery and greater patient awareness the numbers of people treated by SRS continues to rise. As the population of patients treated by SRS increases and greater patient years of follow-up are accrued the reported cases of SRS-related toxicity have also increased. It is, and will continue to be important to monitor patients treated by SRS to better characterize and when possible avoid adverse outcomes.
Radiation Injury
Radiation injury to brain parenchyma has been characterized based on time to development following radiation (4) . Under this characterization "acute reactions" occur within weeks of radiation treatment, "early delayed reactions" appear a few weeks to a few months after irradiation, whereas "late delayed reaction" develop months to years after radiation. The majority of reported complications following SRS occur months to years following the delivery of radiation, thus, consistent with late delayed reactions (5) .
A modified RTOG central nervous system morbidity scoring system has been advanced as a means to assess and compare neurologic toxicity associated with radiosurgery (6) . In this scoring system Grade I toxicity equates to mild neurologic symptoms not requiring medication. Grade II toxicity translates to moderate neurologic symptoms requiring outpatient medications. Grade III toxicity is associated with severe neurologic symptoms requiring outpatient or inpatient medications. Grade IV toxicity translates to life threatening symptoms, including radiation-induced necrosis, requiring surgery. Grade V toxicity equates to fatal toxicity.
Acute Toxicity
Immediate toxicity following SRS has only rarely been reported, and has in general been considered uncommon. Several recent reports have characterized the early/immediate adverse changes following SRS. Chin et al. reported that acute complications to be rare following SRS (7) . The authors of this study retrospectively evaluated 835 patients treated by GKRS for the development of new neurologic deficits, seizure, or death within seven days of SRS. Based on those criteria, 2.2% of treated patients developed side effects, with seizure being the most common complication (7) . Werner-Wasik found that about one-third of patients complained of immediate side effects (8). St. George et al.
reported that about two-thirds of patients treated by radiosurgery developed new immediate adverse symptoms (9) . The authors of this investigation evaluated all complications leading to patient morbidity rather than only neurologic dysfunction. When evaluated in this manner 50% of patients reported non-specific headache, 33% had pain associated with pin sites from the stereotactic head frame, 23% reported new or worsening neurologic deficits, whereas self limiting nausea and fatigue each developed in 20 percent of patients. Overall 91% experienced mild or moderate complications. No significant correlation was observed with prior radiation therapy, lesion type or administration of steroid therapy.
Delayed Toxicity
The most common cited complication following SRS is radiation necrosis (5) . Radiation-induced necrosis is among the most significant side effects stemming from radiation therapy of the central nervous system. Necrosis developing from radiation. exposure presents as a coagulative process predominantly affecting white matter. The events leading up to radiation necrosis is felt to center around small vessel injury. The steps involved irr'this process include vascular injury and release of cytokines that promote and sustains the injury, ultimately resulting in vascular hyalinization and thrombus
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deposition leading to vascular occlusion (10, II). When necrosis does occur following irradiation, it typically develops as a focal process at or near the site of the primary tumor, thus, being geographically associated with the highest dose of radiation treatment (12) . Cerebral edema, that is frequently associated with intracranial tumors, has been demonstrated to enhance fractionated radiation-induced injury and necrosis in the surrounding brain parenchyma (13) . The incidence of radiation necrosis following conventional radiation therapy ranges from 5-24% (14, IS). With stereotactic radiosurgery the presence of pretreatment cerebral edema did not predict for the subsequent development of radiation induced necrosis (16) .
Necrosis most frequently develops at the site of the initial tumor; however, CT and MRI imaging do not distinguish well between necrosis and tumor regrowth (17) . Dynamic susceptibility contrast enhanced MRI (DSC-MRI) is being evaluated as a method to generate maps of regional cerebral blood flow. Using this methodology microscopic blood flow is found to be increased in tumor and diminished in regions of radionecrosis (18) . In addition magnetic resonance spectroscopy shows promise as an imaging tool to differentiate recurrent tumor from secondary necrosis (19) . Metabolic imaging using positron emission tomography is another radiographic tool that has shown promise in distinguishing necrosis from recurrent tumor. The most commonly employed application is based on differential distribution of 18f1uorodeoxyglucose (FOG) in necrotic tissue, normal brain parenchyma and growing tumor (20) . Although under active investigation, the perfect radiographic method for discrimi- Figure 1 : Recurrent neoplasm. Axial contrast enhanced TI weighted MR images displays a nodular, ring-enhancing area of recurrent high-grade glioma within the right temporal lobe with associated mass effect. The patient had received Gamma-Knife radiosurgery for a temporal lobe glioblastoma multiforme 6 months prior. nating between necrosis and recurrence has not been defined. As stated above radiation necrosis and recurrent neoplasm often possess a similar appearance on conventional MR imaging. Both entities can produce contrast-enhancing lesions with associated mass effect and edema. Additional imaging modalities such as PET, MR spectroscopy and perfusion imaging may provide correlative information and allow distinction of these two processes, although often stereotactic or open biopsy is required for a definitive diagnosis. An example of the radiographic similarity that can exist between recurrent neoplasm and radiation necrosis is displayed in Figures I and 2 . Recurrent neoplasm is shown in Figure I and radiation necrosis is presented in Figure 2 . Although necrosis is the most often cited complication following SRS, clinically significant adverse outcome can present without necrosis. A number of risk factors have been found to be associated with development of adverse reactions following SRS. Nedzi et al. found the following factors to be associated with increased risk; lesion size greater than 10 cc, the use of multiple isocenters, tumor homogeneity> lOGy and a maximum tumor dose greater that 25 Gy (21) . Tumor dose inhomogeneity particularly of large lesions had a higher probability than any other factor to be associated with complications (21) .
Dose: Volume
It has long been recognized that volume and dose are critical parameters for radiation therapy and large volumes of brain parenchyma do not tolerate single large fractions of radiation (22) . Kjellberg et al. demonstrated a dose-volume relation-ship for the development of necrosis of patients receiving proton radiosurgery (23) . He developed an isoeffect curve for the occurrence of a 1% incidence of brain necrosis. which has been widely quoted and used as a guide for SRS dosing. Flickinger et al. used an integrated logistic formula to predict the development of brain necrosis following high dose SRS of small volumes (24) . Applying this model to Gamma Knife radiosurgery and 6MV linear accelerator radiosurgery. the dose/volume curve for development of a 3% incidence of brain necrosis was remarkably similar to the I % curve of Kjellberg. Marks et al. summarized 6 clinical studies reporting clinically significant radiation reaction following SRS for arteriovenous malformation. Dose and volume parameters were reviewed for each patient that developed a clinically significant radiation related side effect; this information was then compared to Kjellberg's original I% necrosis isoeffect curve. Clinically significant radiation reactions do not necessarily correlate with necrosis and an analysis based solely on the occurrence of histologically or radiographically confirmed necrosis may underestimate the risk of radiosurgery (25). Whereas, declaring adverse outcomes based only on clinical findings without radiographic conformation may overestimate complication in a group of patients that have competing risk for the development of complication because of recurrent or persistent CNS disease (21) .
Location
Nedzi et al. found no significant association for metastasis location (superficial supratentorial, deep supratentorial or brainstem/ cerebellum) and the development of complications following radiosurgery (21) . However special conditions were employed for radiosurgery treatment of the brain stem and optic pathways. Location was found to be a significant factor predicting for complications following radiosurgery for arteriovenous malformations (26, 27) . The frontal lobe was found to have the lowest risk of damage expression whereas the brainstem and thalamic area had the highest risk of injury following radiosurgery (26, 27) ; additional .areas of the brain were found to have sensitivities between that of the frontal lobe and brain stem (25).
The optic nerves and chiasm have long been recognized to have a lower tolerance for radiation dose than other structures of the brain. For example, the tolerance of cranial nerves II-VI following single fraction radiosurgery for lesions within the cavernous sinus has been evaluated. The results demonstrate a 24% incidence of optic neuropathy if any part of the optic apparatus received> 800 cGy. with zero complications in those that receive < 800 cGy (28) . Cranial nerves III-VI also located in the cavernous sinus tolerated single fraction radiosurgery doses up to 4000 cGy with-few complications. Several reports in general support these findings, the available data demonstrates doses above 8-10 Gy to any portion of the optic apparatus is associated with increased visual loss (28) (29) (30) (31) . When optic neuropathy occurs as a result of SRS it tends to develop within 2 years (30), and the incidence of visual loss rises rapidly with increasing doses above the 8-10 Gy threshold (31) .
Hearing loss has been associated with the delivery of radiation therapy. There are two components to hearing loss, conductive hearing loss related to the external and middle ears and sensorineural hearing loss. Development of a temporary hearing loss during or immediately following radiation therapy can be associated with a conductive hearing loss due to the development of an otitis media. Following treatment for nasopharyngeal carcinoma nearly 50% of patients were found to have a serous otitis media (32) . Hearing loss that develops months to years following radiation treatment have been associated with sensory (cochlear) or neural causes. Autopsies on several of these afflicted patients showed the absence of organ of Corti and VIIIth cranial nerve atrophy (33) . Johannesen et al. observed no loss of hearing with radiation doses less than 54 Gy (34) . Radiation induced hearing impairment occurs nearly 4 times more often for high frequency than low frequency hearing (32) . SRS treatment of acoustic neuroma is associated with risk to the acoustic nerve but also the trigeminal and facial nerve due to a close anatomic relationship. Neuropathies affecting cranial nerve V, VII, and VIII are related to tumor diameter, while multivariate analysis demonstrates facial and trigeminal neuropathy also to be dependent on minimum tumor dose (35) . Flickinger et al. have demonstrated that improvements in radiographic targeting from CT based to MRI based planning has proven beneficial for reducing adverse effects associated with radiosurgery. Comparison of outcome from CT-based and MRIbased plans for treatment of acoustic neuroma demonstrate reduced neuropathies of cranial nerves V, VII and VIII, with no change in the high rate of tumor control (35) . Evaluation of auditory brainstem response and transient evoked otoacustic emission demonstrate that hearing loss following SRS is most closely associated with loss of cochlear function (36) .
Metastases
Metastases represent a special case for radiosurgery; since it has been estimated that about 10% of all cancer patients will ultimately develop brain metastases. Thus, brain metastases is one of the most frequently treated neurologic malignancies. SRS in combination with whole brain radiation is often used for therapy of patients with brain metastasis. Several recent RTOG protocols [9005, 9508] provided guidelines regarding radiosurgery for patients with brain metastasis. Recommended doses were based on the diameter of the metastatic lesion. Stereotactic radiosurgery is especially well tolerated for metastatic disease when compared to primary brain lesio~s (5, 21) . Several explanations have been
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offered to account for this apparent tolerance of metastases for radiosurgery. Metastases are often well circumscribed and grow in an expansive manner with displacrsnent of normal tissue rather than infiltrating in and around normal tissue (37) . Thus, highly conformal radiosurgery of brain metastasis will treat less normal brain tissue when compared to radiosurgery for a primary parenchymal brain lesion. It has also been suggested that metastatic disease is more radioresponsive than primary brain lesions and will tend to shrink rapidly before the inflammatory response to radiosurgery is manifested, thus, limiting the injury to normal brain tissue. Following SRS for brain metastasis between 60 and 80% of patients who were using steroids before radiation could discontinue their steroid usage (38, 39).
Conclusions
Ongoing refinements in the application of stereotactic radiosurgery continue to evolve in an effort to reduce treatmentrelated side effects while maintaining or improving disease control. To date, advancing technology and understanding in radiosurgery have been associated with improved treatment outcome and greater efficacy in reducing normal tissue complications secondary to treatment. Because of the potential side effects of this modality singly or in combination with other modalities, evaluation of more sophisticated treatment strategies will continue to be investigated and deployed when appropriate in order to reduce morbidity related to non-target tissues in patients undergoing treatment for primary and metastatic tumors and/or other primary CNS lesions.
